A new validated RP-HPLC-UV DAD method for assay of bisoprolol fumarate and related substances in tablets
-
Published:2023-01
Issue:1
Volume:68
Page:53-60
-
ISSN:1857-8969
-
Container-title:Macedonian Pharmaceutical Bulletin
-
language:en
-
Short-container-title:Maced. Pharm. Bull.
Author:
Lazarevska Todevska Elena1, Piponski Marjan1, Stefova Marina2
Affiliation:
1. Replek Farm Ltd, Quality Control Department, Kozle 188, 1000 Skopje, R.N. Macedonia 2. Institute of Chemistry, Faculty of Natural Sciences and Mathematics, Ss. Cyril and Methodius University in Skopje, Arhimedova 5, 1000 Skopje, R.N. Macedonia
Abstract
The research focus of this work was development and validation of an efficient analytical method that can be used for separation and determination of related substances of bisoprolol in finished drug product using reversed-phase HPLC with UV-DAD. In a previous systematic study of various stationary phases and elution conditions it was found that several octadecylsilane phases can be successfully employed for separation of the critical pairs of bisoprolol and its related degradation products. Namely, method development led to conclusions that satisfactory resolution and peak shapes were obtained with gradient elution with water with 0.2% perchloric acid and acetonitrile and the reversed-phase columns: Hypersil 3 BDS C18 (100 x 4 mm, 3 m); Zorbax SB C18 (150 x 4.6 mm, 3.5 m); Acquity UPLC BEH C18 (50 x 2.1 mm, 1.7 m), and Xterra MS C18 (100 x 4.6 mm, 3.5 m). Since regular quality control includes the parameter related substances, which is of great importance for the overall quality of dosage forms, this study was oriented towards widening the available validated analytical methods for determination of this parameter. In this work, the results from the validation of the method for determination of related substances of bisoprolol using Zorbax SB C18 150 x 4.6 mm, 3.5 m, are presented. Validation parameters that were tested (linearity, accuracy, precision, selectivity) confirmed that the method is suitable for its intendance and it was used for characterization of the samples from a forced degradation study of bisoprolol tablets.
Keywords: Bisoprolol, RP-HPLC-UV DAD, validation, related substances
Publisher
Macedonian Pharmaceutical Association
Reference19 articles.
1. Arjun, G., Dinakaran, S., Madhavi, B., Naga, M.M., Ramalingam, R., Anisetti, R.N., 2009. A simple HPLC method for quantitation of bisoprolol fumarate in tablet dosage form. Indian Drugs 46(7), 39–42. 2. Bakheit, A.H., Raisuddin, A., Alshahrania, A.D., and El-Azaba, A.S., 2021.Chapter Two –Bisoprolol: A comprehensive profile, Profiles of Drug Substances, Excipients, and Related Methodology 46, 51-89. Available at: https://doi.org/10.1016/bs.podrm.2020.07.006. 3. British Pharmacopoeia, 2018, Stationary Office on behalf of the Medicines and Healthcare products Regulatory Agency (MHRA). Monograph for Bisoprolol fumarate published on 1 January 2018. 4. European Pharmacopoeia, 10th edition, 2019, European Directorate for the Quality of Medicines and Healthcare, Council of Europe, Strasbourg. Мonograph for Bisoprolol fumarate 01/2012:1710. 5. ICH Guideline: Photostability Testing of New Active Substances and Medicinal Products, ICH Topic Q1B, European Medical Agency, CPMP/ICH/279/95, January 1998.
|
|